Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Oct 31;23(1):370–379. doi: 10.1111/jcmm.13941

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

ANK2 is a candidate therapeutic target gene in stomach adenocarcinoma (STAD) hypermutated samples. A, Venn diagram of mutated, differentially expressed, survival related and act as the hub node in a regulatory network identified ANK2 as a potential therapeutic target in the treatment of hypermutated STAD patients. B, ANK2 was highly depressed in hypermutated samples compared with non‐hypermutated and adjacent normal tissue (P < 0.05, Mann‐Whitney test). C, WGCNA exploration uncovered ANK2 as a hub gene associated with some validated tumor suppressors. D, Higher ANK2 expression level is correlated with a significantly better clinical outcome (P = 0.00771, logrank test)